Switzerland's CRISPR Therapeutics Q1 net loss narrows

Overview

• Switzerland-U.S. gene-editing biotech's Q1 revenue missed analyst expectations

• Q1 EPS was -$1.28; net loss narrowed from prior year

• Operating expenses declined yr/yr due to lower employee-related costs

Outlook

• Company expects updates on CTX310, CTX611, and zugo-cel clinical programs in H2 2026

• CRISPR Therapeutics plans to initiate CTX460 and CTX340 clinical trials in 2026

• Vertex completed U.S. regulatory submission for CASGEVY in children ages 5-11; FDA review pending

Result Drivers

• CASGEVY SALES AND ACCESS - Co said Q1 revenue was driven by continued commercial momentum for CASGEVY, with expanded patient access and new pricing agreements

• LOWER OPERATING EXPENSES - Co attributed year-over-year decline in R&D and G&A expenses to decreased employee-related costs

• COLLABORATION EXPENSE SHIFT - Co said lower collaboration expense was due to a higher share of CASGEVY revenue

Company press release: ID:nGNX9R9wJ6

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for CRISPR Therapeutics AG is $78.00, about 51.1% above its May 1 closing price of $51.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.